Table 4.

Comparative safety of pharmacological agents during maintenance therapy in patients with moderate-severe ulcerative colitis, using network meta-analysis. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-defining and row-defining treatment. Bold numbers with darker background are statistically significant. For serious adverse events, odds ratio <1 favors row-defining treatment. For risk of infections, odds ratio <1 favors column-defining treatment. Numbers in parentheses indicate 95% confidence interval.

	RISK OF SERIOUS ADVERSE EVENTS
RISK OF INFECTIONS	Ustekinumab 90mg q8w	1.14 (0.37,3.50)	1.18 (0.50,2.79)	0.43 (0.15,1.22)	0.85 (0.37,1.92)	1.32 (0.56,3.12)	0.87 (0.42,1.79)
	0.63 (0.35,1.16)	Tofacitinib 5mg b.d.	1.03 (0.39,2.71)	0.38 (0.12,1.17)	0.74 (0.29,1.87)	1.15 (0.44,3.02)	0.76 (0.32,1.77)
	1.13 (0.66,1.93)	1.78 (1.02,3.09)	Vedolizumab	0.37 (0.15,0.88)	0.72 (0.49,1.05)	1.12 (0.58,2.14)	0.73 (0.46,1.16)
	0.68 (0.36,1.29)	1.08 (0.56,2.05)	0.61 (0.34,1.09)	Golimumab	1.95 (0.85,4.48)	3.04 (1.27,7.28)	2.00 (0.95,4.20)
	0.89 (0.54,1.47)	1.40 (0.84,2.34)	0.79 (0.60,1.04)	1.31 (0.76,2.25)	Adalimumab	1.56 (0.86,2.82)	1.02 (0.71,1.49)
	0.91 (0.51,1.60)	1.43 (0.80,2.55)	0.80 (0.48,1.34)	1.33 (0.72,2.45)	1.02 (0.64,1.63)	Infliximab	0.66 (0.41,1.04)
	1.11 (0.73,1.69)	1.75 (1.13,2.70)	0.98 (0.70,1.38)	1.62 (1.01,2.62)	1.24 (0.95,1.63)	1.22 (0.83,1.79)	Placebo